Priming with Whole-Cell versus Acellular Pertussis Vaccine
- 7 February 2013
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 368 (6), 581-582
- https://doi.org/10.1056/nejmc1212006
Abstract
From January through August 2012, Oregon had its highest annual tally of reported pertussis cases since 1959. The incidence was highest among infants and children between 10 and 14 years of age. Increasing disease among school-aged children despite high vaccination coverage may be in part a consequence of using acellular pertussis vaccines (diphtheria–tetanus–acellular pertussis, or DTaP), which in 1997 were approved and recommended for all childhood series instead of whole-cell pertussis vaccines (diphtheria–tetanus–whole-cell pertussis, or DTwP).1 We wanted to examine the effectiveness of first-dose DTwP priming in children fully immunized with DTaP beyond their first year of life and in those who subsequently received a tetanus–diphtheria–acellular pertussis (Tdap) booster.Keywords
This publication has 3 references indexed in Scilit:
- Number and Order of Whole Cell Pertussis Vaccines in Infancy and Disease ProtectionPublished by American Medical Association (AMA) ,2012
- Pertussis control: time for something new?Trends in Microbiology, 2012
- Adverse Events Following Pertussis and Rubella VaccinesPublished by American Medical Association (AMA) ,1992